14 results on '"Carrera, Carlo Giovanni"'
Search Results
2. Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)
- Author
-
Gargiulo, Luigi, primary, Ibba, Luciano, additional, Malagoli, Piergiorgio, additional, Amoruso, Fabrizio, additional, Argenziano, Giuseppe, additional, Balato, Anna, additional, Bardazzi, Federico, additional, Burlando, Martina, additional, Carrera, Carlo Giovanni, additional, Damiani, Giovanni, additional, Dapavo, Paolo, additional, Dini, Valentina, additional, Franchi, Chiara, additional, Gaiani, Francesca Maria, additional, Girolomoni, Giampiero, additional, Guarneri, Claudio, additional, Lasagni, Claudia, additional, Loconsole, Francesco, additional, Marzano, Angelo Valerio, additional, Maurelli, Martina, additional, Megna, Matteo, additional, Orsini, Diego, additional, Sampogna, Francesca, additional, Travaglini, Massimo, additional, Valenti, Mario, additional, Costanzo, Antonio, additional, and Narcisi, Alessandra, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Commentary: Unmet Needs in Generalized Pustular Psoriasis in Clinical Practice
- Author
-
Balato, Anna, primary, Ambrogio, Francesca, additional, Burlando, Martina, additional, Carrera, Carlo Giovanni, additional, Chiricozzi, Andrea, additional, Esposito, Maria, additional, Piaserico, Stefano, additional, Teoli, Miriam, additional, and Gisondi, Paolo, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
- Author
-
Chiricozzi, Andrea, primary, Megna, Matteo, additional, Giunta, Alessandro, additional, Carrera, Carlo Giovanni, additional, Dapavo, Paolo, additional, Balato, Anna, additional, Malagoli, Piergiorgio, additional, Mazzoccoli, Stella, additional, Parodi, Aurora, additional, Sabatino, Silvia, additional, Buzzoni, Carlotta, additional, Huang, Chu-Han, additional, and Narcisi, Alessandra, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
- Author
-
Gargiulo, Luigi, primary, Ibba, Luciano, additional, Malagoli, Piergiorgio, additional, Amoruso, Fabrizio, additional, Argenziano, Giuseppe, additional, Balato, Anna, additional, Bardazzi, Federico, additional, Burlando, Martina, additional, Carrera, Carlo Giovanni, additional, Damiani, Giovanni, additional, Dapavo, Paolo, additional, Dini, Valentina, additional, Fabbrocini, Gabriella, additional, Franchi, Chiara, additional, Gaiani, Francesca Maria, additional, Girolomoni, Giampiero, additional, Guarneri, Claudio, additional, Lasagni, Claudia, additional, Loconsole, Francesco, additional, Marzano, Angelo Valerio, additional, Megna, Matteo, additional, Sampogna, Francesca, additional, Travaglini, Massimo, additional, Costanzo, Antonio, additional, and Narcisi, Alessandra, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
- Author
-
Fargnoli, Maria Concetta, primary, Bardazzi, Federico, additional, Bianchi, Luca, additional, Dapavo, Paolo, additional, Fabbrocini, Gabriella, additional, Gisondi, Paolo, additional, Micali, Giuseppe, additional, Offidani, Anna Maria, additional, Pellacani, Giovanni, additional, Skroza, Nevena, additional, Angileri, Rosa Giuseppa, additional, Burlando, Martina, additional, Campanati, Anna, additional, Carrera, Carlo Giovanni, additional, Chiricozzi, Andrea, additional, Conti, Andrea, additional, Simone, Clara De, additional, Di Lernia, Vito, additional, Errichetti, Enzo, additional, Galluzzo, Marco, additional, Guarneri, Claudio, additional, Lasagni, Claudia, additional, Lembo, Serena, additional, Loconsole, Francesco, additional, Megna, Matteo, additional, Musumeci, Maria Letizia, additional, Prignano, Francesca, additional, Richetta, Antonio Giovanni, additional, Trovato, Emanuele, additional, Venturini, Marina, additional, Peris, Ketty, additional, and Pinton, Piergiacomo Calzavara, additional
- Published
- 2023
- Full Text
- View/download PDF
7. A Multidisciplinary Approach to Patients with Psoriasis and a History of Malignancies or On-Treatment for Solid Tumors: A Narrative Literature Review.
- Author
-
Denaro, Nerina, Nazzaro, Gianluca, Murgia, Giulia, Scarfì, Federica, Cauchi, Carolina, Carrera, Carlo Giovanni, Cattaneo, Angelo, Solinas, Cinzia, Scartozzi, Mario, Marzano, Angelo Valerio, Garrone, Ornella, and Passoni, Emanuela
- Subjects
LITERATURE reviews ,PSORIASIS ,SYMPTOMS ,TUMORS ,DISEASE risk factors - Abstract
Psoriasis is a chronic immune-mediated disease that is linked to an increased risk of cancer. Although numerous studies have explored whether neoplasms are concurrent conditions or are induced by psoriasis, a definitive definition remains elusive. In this study, we conducted a comprehensive narrative literature review to offer practical guidance to oncologists and dermatologists regarding the initiation and discontinuation of biologics for psoriasis. The findings indicate that a customized approach is recommended for each patient, and that a history of malignancies does not constitute an absolute contraindication for biologics. Growing evidence supports the treatment of selected patients, emphasizing a nuanced assessment of benefits and risks. There is a lack of data specifying a safe timeframe to initiate biologics following a neoplasm diagnosis due to influences from cancer-related and patient-specific characteristics impacting prognosis. Some patients may continue anti-psoriasis therapy during cancer treatments. Enhanced comprehension of the biological mechanisms in cancer progression and the immune microenvironment of psoriasis holds promise for refining therapeutic strategies. In conclusion, a personalized treatment approach necessitates collaboration between oncologists and dermatologists, considering factors such as cancer prognosis, psoriasis clinical manifestations, patient characteristics, and preferences when making treatment decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
- Author
-
Avallone, Gianluca, primary, Maronese, Carlo Alberto, additional, Murgia, Giulia, additional, Carrera, Carlo Giovanni, additional, Mastorino, Luca, additional, Roccuzzo, Gabriele, additional, Dapavo, Paolo, additional, Alberti-Violetti, Silvia, additional, Quaglino, Pietro, additional, Ribero, Simone, additional, and Marzano, Angelo Valerio, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
- Author
-
Stingeni, Luca, primary, Malara, Giovanna, additional, Conti, Andrea, additional, Di Costanzo, Luisa, additional, Carrera, Carlo Giovanni, additional, Burlando, Martina, additional, Malagoli, Piergiorgio, additional, Musumeci, Maria Letizia, additional, Bardazzi, Federico, additional, Brazzelli, Valeria, additional, Amerio, Paolo, additional, De Simone, Clara, additional, Trevisini, Sara, additional, Balato, Anna, additional, Megna, Matteo, additional, Loconsole, Francesco, additional, De Felice, Catia, additional, Bartezaghi, Marta, additional, Rausa, Alice, additional, Aloisi, Elisabetta, additional, Orsenigo, Roberto, additional, and Costanzo, Antonio, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach
- Author
-
De Simone, Clara, Dapavo, Paolo, Malagoli, Piergiorgio, Martella, Alessandro, Campanati, Anna, Campione, Elena, Errichetti, Enzo, Franchi, Chiara, Gambardella, Alessio, Megna, Matteo, Osti, Federica, Ribero, Simone, Zagni, Giovanni, Calzavara-Pinton, Piergiacomo, Fabbrocini, Gabriella, Amoruso, Giuseppe Fabrizio, Baglieri, Francesco, Biamonte, Anna Silvia, Bianchelli, Tommaso, Bigi, Laura, Bortoli, Jarno, Brunetti, Bruno, Buligan, Cinzia, Cagni, Elisabetta, Calderoni, Ombretta, Caputo, Alighiero, Carrera, Carlo Giovanni, Carugno, Andrea, Chersi, Karin, Cicchelli, Stefano, De Natale, Flora, Di Maria, Domenico, Ferrari, Angelo Salvatore, Fogli, Emanuela, Forconi, Riccardo, Galeazzi, Augusto, Giovannini, Andrea, Giura, Maria Teresa, Iuculano, Massimo, Lazzaretti, Giuseppe, Leporati, Claudia, Magnanini, Massimiliano, Marconi, Barbara, Maruccia, Adriana, Miglietta, Roberta, Minuti, Anna, Mocci, Luigi, Modica, Sonia, Narcisi, Alessandra, Odorici, Giulia, Pazzaglia, Massimiliano, Peila, Rossana, Pertusi, Ginevra, Pezza, Michele, Pezzullo, Elio, Puccia, Nunzio, Raulo, Umberto, Rossi, Mariateresa, Rusignuolo, Sergio, Sapienza, Giada, Savarese, Catello, Scalisi, Mariaelena, Strippoli, Davide, Stroppiana, Elena, Tiberio, Rossana, Trischitta, Antonino, Tucci, Maria Giovanna, Vaira, Fabrizio, Verrone, Anna, Villa, Lucia, Zagni, Fabio, Zoccali, Andrea, De Simone, C, Dapavo, P, Malagoli, P, Martella, A, Campanati, A, Campione, E, Errichetti, E, Franchi, C, Gambardella, A, Megna, M, Osti, F, Ribero, S, Zagni, G, Calzavara-Pinton, P, Fabbrocini, G, Amoruso, G, Baglieri, F, Biamonte, A, Bianchelli, T, Bigi, L, Bortoli, J, Brunetti, B, Buligan, C, Cagni, E, Calderoni, O, Caputo, A, Carrera, C, Carugno, A, Chersi, K, Cicchelli, S, De Natale, F, Di Maria, D, Ferrari, A, Fogli, E, Forconi, R, Galeazzi, A, Giovannini, A, Giura, M, Iuculano, M, Lazzaretti, G, Leporati, C, Magnanini, M, Marconi, B, Maruccia, A, Miglietta, R, Minuti, A, Mocci, L, Modica, S, Narcisi, A, Odorici, G, Pazzaglia, M, Peila, R, Pertusi, G, Pezza, M, Pezzullo, E, Puccia, N, Raulo, U, Rossi, M, Rusignuolo, S, Sapienza, G, Savarese, C, Scalisi, M, Strippoli, D, Stroppiana, E, Tiberio, R, Trischitta, A, Tucci, M, Vaira, F, Verrone, A, Villa, L, Zagni, F, Zoccali, A, De Simone, Clara, Dapavo, Paolo, Malagoli, Piergiorgio, Martella, Alessandro, Campanati, Anna, Campione, Elena, Errichetti, Enzo, Franchi, Chiara, Gambardella, Alessio, Megna, Matteo, Osti, Federica, Ribero, Simone, Zagni, Giovanni, Calzavara-Pinton, Piergiacomo, Fabbrocini, Gabriella, Amoruso, Giuseppe Fabrizio, Baglieri, Francesco, Biamonte, Anna Silvia, Bianchelli, Tommaso, Bigi, Laura, Bortoli, Jarno, Brunetti, Bruno, Buligan, Cinzia, Cagni, Elisabetta, Calderoni, Ombretta, Caputo, Alighiero, Carrera, Carlo Giovanni, Carugno, Andrea, Chersi, Karin, Cicchelli, Stefano, De Natale, Flora, Di Maria, Domenico, Ferrari, Angelo Salvatore, Fogli, Emanuela, Forconi, Riccardo, Galeazzi, Augusto, Giovannini, Andrea, Giura, Maria Teresa, Iuculano, Massimo, Lazzaretti, Giuseppe, Leporati, Claudia, Magnanini, Massimiliano, Marconi, Barbara, Maruccia, Adriana, Miglietta, Roberta, Minuti, Anna, Mocci, Luigi, Modica, Sonia, Narcisi, Alessandra, Odorici, Giulia, Pazzaglia, Massimiliano, Peila, Rossana, Pertusi, Ginevra, Pezza, Michele, Pezzullo, Elio, Puccia, Nunzio, Raulo, Umberto, Rossi, Mariateresa, Rusignuolo, Sergio, Sapienza, Giada, Savarese, Catello, Scalisi, Mariaelena, Strippoli, Davide, Stroppiana, Elena, Tiberio, Rossana, Trischitta, Antonino, Tucci, Maria Giovanna, Vaira, Fabrizio, Verrone, Anna, Villa, Lucia, Zagni, Fabio, and Zoccali, Andrea
- Subjects
Aerosols ,long-term ,proactive management ,Dermatology ,psoriasis ,Betamethasone ,Drug Combinations ,Treatment Outcome ,Recurrence ,consensus ,Cal/BD ,adherence ,consensu ,Humans ,Dermatologic Agents ,psoriasi - Abstract
Background: Although long-term management of psoriasis is paramount, this approach is challenging in clinical practice. In the recent PSO-LONG trial, a fixed-dose combination of betamethasone dipropionate (BD) and calcipotriol (Cal) foam applied twice a week on non-consecutive days for 52 weeks (proactive treatment) reduced the risk of relapse. However, the role of Cal/BD foam in the long-term management of psoriasis needs further clarifications. The ProActive Management (PAM) program, a nationwide Italian project, aims at reaching a consensus on the role of proactive management of psoriasis. Methods: A steering committee generated some statements through the nominal group technique (NGT). The statements were voted by an expert panel in an adapted Delphi voting process. Results: Eighteen statements were proposed, and the majority of them (14/18) reached a consensus during the Delphi voting. The need to provide long-term proactive topical treatment to reduce the risk of relapse for the treatment of challenging diseases sites or in patients where phototherapy or systemic therapies are contraindicated/ineffective was widely recognized. A consensus was reached about the possibility to associate the proactive treatment with systemic and biological therapies, without the need for dose intensification, thus favoring a prolonged remission. Moreover, the proactive treatment was recognized as more effective than weekend therapy in increasing time free from relapses. Approaches to improve adherence, on the other hand, need further investigation. Conclusions: The inclusion in guidelines of a proactive strategy among the effective treatment options will be a fundamental step in the evolution of a mild-moderate psoriasis therapeutic approach.
- Published
- 2022
11. Cheilitis granulomatosa associated with lupus erythematosus discoid and treated with methotrexate: report of a case
- Author
-
Nazzaro, Gianluca, Muratori, Simona, Carrera, Carlo Giovanni, Coggi, Antonella, and Gianotti, Raffaele
- Subjects
Lupus erythematosus, discoid ,Methotrexate ,Melkersson-Rosenthal Syndrome ,skin and connective tissue diseases - Abstract
We present the rare case of a 47-year-old patient, suffering from cheilitis granulomatosa and lupus erythematosus discoid: this association is really exceptional because only once reported in English literature. In addition, the treatment of cheilitis granulomatosa is a challenge for the dermatologist: the gold standard, represented by steroids, is in fact designed as a short-time option. Our report confi rms the good efficacy of methotrexate as a steroid-sparing agent.
- Published
- 2015
12. Cheilitis granulomatosa associated with lupus erythematosus discoid and treated with methotrexate: report of a case
- Author
-
Nazzaro, Gianluca, primary, Muratori, Simona, additional, Carrera, Carlo Giovanni, additional, Coggi, Antonella, additional, and Gianotti, Raffaele, additional
- Published
- 2015
- Full Text
- View/download PDF
13. Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study
- Author
-
Luca Stingeni, Giovanna Malara, Andrea Conti, Luisa Di Costanzo, Carlo Giovanni Carrera, Martina Burlando, Piergiorgio Malagoli, Maria Letizia Musumeci, Federico Bardazzi, Valeria Brazzelli, Paolo Amerio, Clara De Simone, Sara Trevisini, Anna Balato, Matteo Megna, Francesco Loconsole, Catia De Felice, Marta Bartezaghi, Alice Rausa, Elisabetta Aloisi, Roberto Orsenigo, Antonio Costanzo, Stingeni, Luca, Malara, Giovanna, Conti, Andrea, Di Costanzo, Luisa, Carrera, Carlo Giovanni, Burlando, Martina, Malagoli, Piergiorgio, Musumeci, Maria Letizia, Bardazzi, Federico, Brazzelli, Valeria, Amerio, Paolo, De Simone, Clara, Trevisini, Sara, Balato, Anna, Megna, Matteo, Loconsole, Francesco, De Felice, Catia, Bartezaghi, Marta, Rausa, Alice, Aloisi, Elisabetta, Orsenigo, Roberto, and Costanzo, Antonio
- Subjects
Hospital Anxiety and Depression Scale ,Clinical, Cosmetic and Investigational Dermatology ,patient-reported outcomes ,Dermatology Quality of Life Index ,PASI ,Dermatology ,patient-reported outcome ,plaque psoriasis - Abstract
Luca Stingeni,1 Giovanna Malara,2,3 Andrea Conti,4 Luisa Di Costanzo,5 Carlo Giovanni Carrera,6 Martina Burlando,7 Piergiorgio Malagoli,8 Maria Letizia Musumeci,9 Federico Bardazzi,10 Valeria Brazzelli,11 Paolo Amerio,12 Clara De Simone,13,14 Sara Trevisini,15 Anna Balato,16 Matteo Megna,17 Francesco Loconsole,18 Catia De Felice,19 Marta Bartezaghi,20 Alice Rausa,20 Elisabetta Aloisi,20 Roberto Orsenigo,20 Antonio Costanzo21,22 On behalf of the SUPREME Study Group1Dermatology Section, Medical and Surgical Department, University of Perugia, Perugia, Italy; 2Dermatology Unit, Hospital âBianchi Melacrino Morelliâ, Reggio Calabria, Italy; 3Department of Dermatology, Papardo Hospital, Messina, Italy; 4Dermatologic Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, Rimini, Italy; 5Department of Dermatology, âGaetano Rummoâ Hospital, Benevento UOC Dermatologia, AO G. Rummo, Benevento, Italy; 6U.O. Dermatologia, Fondazione IRCCS Caâ Granda - Ospedale Maggiore Policlinico, Milano, Italy; 7IRCCS San Martino Polyclinic Hospital, Di.S.Sal. Section of Dermatology, Genoa, Italy; 8Dermatology Unit IRCCS Policlinico San Donato, Milan, Italy; 9Dermatology Clinic, University of Catania, Catania, Italy; 10Division of Dermatology, University Hospital Policlinico âS. Orsola-Malpighiâ, Bologna, Italy; 11Institute of Dermatology, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy; 12Dermatologic Clinic, G. DâAnnunzio University, Chieti, Italy; 13Istituto di Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy; 14Fondazione Policlinico Universitario A. Gemelli â IRCCS, Rome, Italy; 15Dermatology Department, University of Trieste, Trieste, Italy; 16Dermatology Unit, University of Campania âLuigi Vanvitelliâ, Naples, Italy; 17Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 18Department of Biomedical Sciences and Human Oncology, University of Bari, Bari, Italy; 19Department of Clinical Dermatology, Centre for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy; 20Novartis Farma SpA, Origgio, Italy; 21Unit of Dermatology, IRCCS Humanitas Research Hospital, Milan, Italy; 22Department of Biomedical Sciences, Humanitas University, Milan, ItalyCorrespondence: Luca Stingeni, Dermatology Section, Medical and Surgical Department, University of Perugia, Perugia, Italy, Tel +39075-5783881, Email luca.stingeni@unipg.itPurpose: Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc analysis from the Phase 3b SUPREME study explored gender-related differences in patient characteristics and efficacy of secukinumab 300 mg on Psoriasis Area and Severity Index (PASI) 75/90/100 and impact on QoL using the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis through week 24.Patients and Methods: The proportion of patients achieving PASI 75/90/100 was computed using a nonresponder imputation approach. Differences between cohorts were analyzed using a logistic regression model. The mean change from baseline in DLQI was computed using the Wilcoxon test.Results: Among the 433 patients (males: 71.6%), females had a higher DLQI than males at baseline (13.1 vs 9.5; P< 0.0001). Males had a slightly higher response for PASI 90 than females at week 16 (80.7% vs 78.1%; P=0.0779) and 24 (83.2% vs 79.7%; P=0.0319). No differences were observed between genders in PASI 100/75 responses at week 24. Both genders showed an improvement in DLQI with secukinumab at week 24 (â 10.9 vs â 8.1, respectively, in females vs males; P=0.0004).Conclusion: In summary, secukinumab was effective in the treatment of psoriasis, irrespective of gender.Keywords: plaque psoriasis, PASI, patient-reported outcomes, Dermatology Quality of Life Index, Hospital Anxiety and Depression Scale
- Published
- 2023
14. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
- Author
-
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, Paolo Dapavo, Gabriella Fabbrocini, Paolo Gisondi, Giuseppe Micali, Anna Maria Offidani, Giovanni Pellacani, Nevena Skroza, Rosa Giuseppa Angileri, Martina Burlando, Anna Campanati, Carlo Giovanni Carrera, Andrea Chiricozzi, Andrea Conti, Clara De Simone, Vito Di Lernia, Enzo Errichetti, Marco Galluzzo, Claudio Guarneri, Claudia Lasagni, Serena Lembo, Francesco Loconsole, Matteo Megna, Maria Letizia Musumeci, Francesca Prignano, Antonio Giovanni Richetta, Emanuele Trovato, Marina Venturini, Ketty Peris, Piergiacomo Calzavara Pinton, Fargnoli, Maria Concetta, Bardazzi, Federico, Bianchi, Luca, Dapavo, Paolo, Fabbrocini, Gabriella, Gisondi, Paolo, Micali, Giuseppe, Offidani, Anna Maria, Pellacani, Giovanni, Skroza, Nevena, Angileri, Rosa Giuseppa, Burlando, Martina, Campanati, Anna, Carrera, Carlo Giovanni, Chiricozzi, Andrea, Conti, Andrea, Simone, Clara De, Di Lernia, Vito, Errichetti, Enzo, Galluzzo, Marco, Guarneri, Claudio, Lasagni, Claudia, Lembo, Serena, Loconsole, Francesco, Megna, Matteo, Musumeci, Maria Letizia, Prignano, Francesca, Richetta, Antonio Giovanni, Trovato, Emanuele, Venturini, Marina, Peris, Ketty, and Pinton, Piergiacomo Calzavara
- Subjects
brodalumab ,Delphi ,consensus ,statement ,psoriasis ,consensu ,brodalumab therapy psoriasis ,General Medicine - Abstract
Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of moderate-to-severe psoriasis. Based on published literature and their clinical experience a steering committee drafted 17 statements covering 7 domains specific to the treatment of moderate-to-severe psoriasis with brodalumab. A panel of 32 Italian dermatologists indicated their level of agreement using a 5-point Likert scale (from 1 = “strongly disagree” to 5 = “strongly agree”) using an online modified Delphi method. After the first round of voting (32 participants), positive consensus was reached for 15/17 (88.2%) of the proposed statements. Following a face-to-face virtual meeting, the steering committee decided that 5 statements would form “main principles” and 10 statements formed the final list. After a second round of voting, consensus was reached in 4/5 (80%) of the main principles and 8/10 (80%) for consensus statements. The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis.
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.